PGNY Stock Analysis: Progyny | NASDAQ
Healthcare Plans | NASDAQ, USA | Market Cap: 1.973m USD | 12M Return: 16.5% | US74340E1038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.8M
EPS Trend: 73.3%
Qual. Beats: 2
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Progyny, Inc. (NASDAQ: PGNY) is a U.S.-based benefits management company specializing in fertility, family-building, and womens health benefits solutions. Its offerings include a differentiated fertility benefits plan design featuring a smart cycle treatment bundle, concierge-style member support, access to a selective network of fertility specialists, and an integrated pharmacy benefits solution (Progyny Rx) that provides treatment-related medications. The company also extends its platform into pregnancy and postpartum care, menopause and midlife health, parental and child wellbeing, and benefit and leave navigation, along with a reimbursement program covering services such as adoption, surrogacy, doula support, and travel for medical care.
Progyny was incorporated in 2008 and is headquartered in New York, New York. It was originally founded as Auxogyn, Inc. before rebranding to its current name in 2015, and completed its IPO in October 2019. The company operates in the employer-sponsored health benefits sector, selling its fertility and family-building solutions to employers and health plans on a B2B2C basis, with employees then accessing the benefits as part of their workplace coverage - a distribution model that has grown as more U.S. employers add fertility benefits to attract and retain talent.
- Fertility benefit utilization rates drive revenue beats
- Progyny Rx pharmacy margins expand with scale
- Competition from Maven and Carrot pressures employer win rates
| Net Income: 78.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.30 > 0.02 and ΔFCF/TA 5.46 > 1.0 |
| NWC/Revenue: 20.82% < 20% (prev 30.11%; Δ -9.29% < -1%) |
| CFO/TA 0.35 > 3% & CFO 247.2m > Net Income 78.6m |
| Net Debt (-187.5m) to EBITDA (127.1m): -1.48 < 3 |
| Current Ratio: 2.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.1m) vs 12m ago -8.36% < -2% |
| Gross Margin: 24.57% > 18% (prev 22.34%; Δ 2.23% > 0.5%) |
| Asset Turnover: 177.5% > 50% (prev 163.2%; Δ 14.30% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.38 (Total Current Assets 513.0m - Total Current Liabilities 240.1m) / Total Assets 715.8m |
| B: 0.36 (Retained Earnings 255.1m / Total Assets 715.8m) |
| C: 0.16 (EBIT TTM 119.8m / Avg Total Assets 738.4m) |
| D: 1.73 (Book Value of Equity 453.3m / Total Liabilities 262.6m) |
| Altman-Z'' = 6.57 = AAA |
| DSRI: 0.90 (Receivables 257.5m/271.9m, Revenue 1.31b/1.24b) |
| GMI: 0.91 (GM 22.34% / 24.57%) |
| AQI: 1.42 (AQ_t 0.22 / AQ_t-1 0.16) |
| SGI: 1.06 (Revenue 1.31b / 1.24b) |
| TATA: -0.24 (NI 78.6m - CFO 247.2m) / TA 715.8m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of August 27, 2026, the stock is trading at USD 26.37 with a total of 1,117,305 shares traded. Over the past week, the price has changed by +3.29%, over one month by -16.52%, over three months by +5.27% and over the past year by +16.48%.
Current recommended Stop Loss: 24.50 (which is 7.1% or 1.8 ATR below the current price).
Progyny has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PGNY.
- StrongBuy: 4
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.7 | 27.9% |
P/E Trailing = 27.9457
P/E Forward = 13.1926
P/S = 1.4944
P/B = 4.3522
Revenue TTM = 1.31b USD
EBIT TTM = 119.8m USD
EBITDA TTM = 127.1m USD
Long Term Debt = 22.5m USD (estimated: total debt 27.0m - short term 4.47m)
Short Term Debt = 4.47m USD (from shortTermDebt, last quarter)
Debt = 49.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.5m
Net Debt = -187.5m USD (calculated: Debt 49.5m - CCE 236.9m)
Enterprise Value = 1.79b USD (1.97b + Debt 49.5m - CCE 236.9m)
Interest Coverage Ratio = unknown (Ebit TTM 119.8m / Interest Expense TTM 0.0)
EV/FCF = 8.19x (Enterprise Value 1.79b / FCF TTM 218.0m)
FCF Yield = 12.21% (FCF TTM 218.0m / Enterprise Value 1.79b)
FCF Margin = 16.63% (FCF TTM 218.0m / Revenue TTM 1.31b)
Net Margin = 6.00% (Net Income TTM 78.6m / Revenue TTM 1.31b)
Gross Margin = 24.57% ((Revenue TTM 1.31b - Cost of Revenue TTM 988.7m) / Revenue TTM)
Gross Margin QoQ = 25.48% (prev 25.29%)
Tobins Q-Ratio = 2.49 (Enterprise Value 1.79b / Total Assets 715.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 49.5m)
Taxrate = 34.38% (41.2m / 119.8m)
NOPAT = 78.6m (EBIT 119.8m * (1 - 34.38%))
Current Ratio = 2.14 (Total Current Assets 513.0m / Total Current Liabilities 240.1m)
Debt / Equity = 0.11 (Debt 49.5m / totalStockholderEquity, last quarter 453.3m)
Debt / EBITDA = -1.48 (Net Debt -187.5m / EBITDA 127.1m)
Debt / FCF = -0.86 (Net Debt -187.5m / FCF TTM 218.0m)
Total Stockholder Equity = 492.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.65% (Net Income 78.6m / Total Assets 715.8m)
RoE = 15.98% (Net Income TTM 78.6m / Total Stockholder Equity 492.2m)
RoCE = 23.29% (EBIT 119.8m / Capital Employed (Equity 492.2m + L.T.Debt 22.5m))
RoIC = 18.96% (NOPAT 78.6m / Invested Capital 414.7m)
WACC = 6.69% (E(1.97b)/V(2.02b) * Re(6.86%) + D(49.5m)/V(2.02b) * Rd(0.0%) * (1-Tc(0.34)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.10 | Cagr: -8.80%
[DCF] Terminal Value 77.91% ; FCFF base≈206.9m ; Y1≈236.4m ; Y5≈344.9m
[DCF] Fair Price = 70.15 (EV 5.19b - Net Debt -187.5m = Equity 5.38b / Shares 76.7m; r=8.35% [WACC [floored]]; 5y FCF grow 14.61% → 2.50% )
EPS Correlation: 73.30 | EPS CAGR: 37.10% | SUE: 3.25 | # QB: 2
Revenue Correlation: 98.69 | Revenue CAGR: 8.89% | SUE: 0.18 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.51 | Chg30d=-2.24% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=+1.37% | Revisions=+57% | GrowthEPS=+10.2% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=2.30 | Chg30d=+2.40% | Revisions=+57% | GrowthEPS=+10.5% | GrowthRev=+9.9%
[Analyst] Revisions Ratio: +50% (up=9, down=2)